ZLAB Zai Lab Ltd
Pharmaceutical Preparations · Nasdaq · SEC CIK 1704292 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.0%
TTM net income YoY4.1%
TTM EPS YoY5.3%
Revenue 3-yr CAGR18.8%
Net income 3-yr CAGR—
Margins
Gross margin54.7%
Operating margin-63.0%
Net margin-44.9%
FCF margin-37.0%
EBITDA margin-60.1%
Returns
ROE-30.0%
ROA-18.2%
ROIC (approx.)-779.4%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets45.0%
Debt / equity0.00x
Current ratio2.04x
Interest coverage-45.16x
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $460.16M | $398.99M |
| Cost of revenue | $190.52M | $147.12M |
| Gross profit | $269.64M | $251.87M |
| R&D expense | $220.90M | $234.50M |
| SG&A expense | $277.61M | $298.74M |
| Operating income | -$229.43M | -$282.12M |
| Interest expense | $5.21M | $2.25M |
| Pretax income | -$178.46M | -$257.10M |
| Income tax | -$2.93M | $0 |
| Net income | -$175.54M | -$257.10M |
| EBITDA | -$214.42M | -$270.26M |
| EPS (basic) | -0.16 | -0.26 |
| EPS (diluted) | -0.16 | -0.26 |
| Weighted avg. shares (diluted) | 1.10B | 989.48M |
| Balance sheet | ||
| Cash & equivalents | $679.57M | $449.67M |
| Short-term investments | $10.00M | $330.00M |
| Receivables | $106.12M | $85.18M |
| Inventory | $74.75M | $39.88M |
| Current assets | $1.02B | $1.05B |
| PP&E, net | $47.39M | $47.96M |
| Intangibles | $76.14M | $56.03M |
| Total assets | $1.17B | $1.19B |
| Current liabilities | $416.17M | $299.38M |
| Short-term debt | $204.53M | $131.71M |
| Total liabilities | $456.88M | $344.86M |
| Shareholders' equity | $715.50M | $840.90M |
| Shares outstanding | 1.11B | 1.08B |
| Cash flow statement | ||
| Operating cash flow | -$150.79M | -$214.87M |
| Capital expenditure | $8.10M | $5.66M |
| Free cash flow | -$158.89M | -$220.53M |
| Investing cash flow | $307.87M | -$375.19M |
| Financing cash flow | $72.35M | $349.89M |
| Depreciation & amortization | $15.01M | $11.86M |
| Stock-based compensation | $65.60M | $70.65M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.